SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-21-008214
Filing Date
2021-04-05
Accepted
2021-04-05 16:07:58
Documents
4
Period of Report
2021-03-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K aytu20210401_8k.htm 8-K 35569
2 EXHIBIT 10.1 - EISENSTADT EMPLOYMENT AGREEMENT ex_239175.htm EX-10.1 79464
3 EXHIBIT 99.1 - NATESTO TERMINATION AND DIVESTITURE ex_239051.htm EX-99.1 7530
4 EXHIBIT 99.2 - RICHARD EISENSTADT AS NEW CFO ANNOUNCEMENT ex_239052.htm EX-99.2 8408
  Complete submission text file 0001437749-21-008214.txt   132622
Mailing Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112
Business Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112 (720) 437-6580
AYTU BIOPHARMA, INC (Filer) CIK: 0001385818 (see all company filings)

IRS No.: 470883144 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-38247 | Film No.: 21805392
SIC: 2834 Pharmaceutical Preparations